Meeting
2013 Gastrointestinal Cancers Symposium
Phase II study of sorafenib and capecitabine (SorCape) in previously treated metastatic colorectal cancer (mCRC): NCT01471353.
Authors
Thomas George
University of Florida
Thomas George , Alison Ivey , Long Dang , Karen Daily , Wei Hou , Dana Viviano , Scott Watson , Renee Granicz , Margaret McEwan , Hui Yan , Carmen Allegra
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01471353
Citation
J Clin Oncol 31, 2013 (suppl 4; abstr489)
DOI
10.1200/jco.2013.31.4_suppl.489
Abstract #
489
Poster Bd #
C45
Abstract Disclosures
Similar Posters
Poster
2014 Gastrointestinal Cancers Symposium
Planned interim analysis of phase II study of sorafenib and capecitabine (SorCape) in previously treated metastatic colorectal cancer (mCRC): NCT01471353.
First Author: Thomas J. George
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2021 ASCO Annual Meeting
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Zanzalintinib (XL092) plus atezolizumab versus regorafenib in previously treated MSS/MSI-low metastatic colorectal cancer (mCRC): The randomized phase 3 STELLAR-303 study.
First Author: Anwaar Saeed